The global Structural Cardiac Devices Market size was valued at $4.1 billion in 2016 and is expected to grow at a CAGR of 9.15% over the forecast period. The large prevalence of targeted diseases is a major driver of the market. Nearly 60 million people in the United States have structural flaws in their minds. This makes up about 20-25% of the total population. This represents a broad range of devices dealing with structural heart defects. Structural heart disease (SHD) is a broad category of percutaneous treatment for patients with acquired and congenital heart disease (CHD), including functional and structural abnormalities of the heart chamber, proximal versus blood vessels, and heart valves.
A full report of Structural Cardiac Devices Market available at https://www.orionmarketreports.com/structural-heart-devices-market/17228/
The major players operating in the structural heart devices market are Edwards Lifesciences Corporation (US), Medtronic plc (Ireland), Abbott (US), Boston Scientific Corporation (US), and LivaNova plc (UK).
Global Medical Bed Market Segmentations
By Product
• Repair Devices
• Replacement Valves
By Indication
• Atrial Septal Defect (ASD)
• Ventricular Septal Defect (VSD)
• Patent Foramen Ovale (PFO)
• Aortic Valve Stenosis
• Others
By Age Group
• Pediatric
• Adults
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
